Safety and Effectiveness of an Adjuvant in Improving Immune Response to Hepatitis B Virus Vaccine in HIV Infected Individuals
Public ClinicalTrials.gov record NCT00272493. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Improving Immune Response to Hepatitis B Vaccine in HIV-positive Subjects Using Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) as a Vaccine Adjuvant: A Phase II Open-Label Pilot Study
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a naturally occurring substance that is made by the body in response to infection or inflammation, and greatly improves cellular immune responses. The purpose of this study is to evaluate the safety and effectiveness of GM-CSF as an adjuvant to improve the immune response to hepatitis B virus (HBV) vaccination in HIV infected individuals.
Study identification
- NCT ID
- NCT00272493
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 48 participants
Conditions and interventions
Conditions
Interventions
- Hepatitis B virus vaccine with GM-CSF adjuvant Biological
- Hepatitis B virus vaccine Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Not listed
- Primary completion
- Nov 2007 (Actual)
- Completion
- Sep 2008 (Actual)
- Last update posted
- Oct 25, 2021
Ends 2008
United States locations
- U.S. sites
- 11
- U.S. states
- 6
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Northwestern University CRS | Chicago | Illinois | 60611-3015 | — |
| Rush Univ. Med. Ctr. ACTG CRS | Chicago | Illinois | 60611 | — |
| Washington U CRS | St Louis | Missouri | 63108-2138 | — |
| NY Univ. HIV/AIDS CRS | New York | New York | 10016-6481 | — |
| Univ. of Rochester ACTG CRS | Rochester | New York | 14642-0001 | — |
| Univ. of Rochester ACTG CRS | Durham | North Carolina | 27710 | — |
| Univ. of Cincinnati CRS | Cincinnati | Ohio | 45267-0405 | — |
| Case CRS | Cleveland | Ohio | 44106-5083 | — |
| MetroHealth CRS | Cleveland | Ohio | 44109-1998 | — |
| The Ohio State Univ. AIDS CRS | Columbus | Ohio | 43210 | — |
| University of Washington AIDS CRS | Seattle | Washington | 98104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00272493, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 25, 2021 · Synced Oct 30, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00272493 live on ClinicalTrials.gov.